| Literature DB >> 11705352 |
Abstract
Biologics in development for the treatment of moderate to severe plaque-type psoriasis are discussed in this article. Immunomodulators used as therapeutic, pathogenic probes will continue to identify targets that play primary roles in the pathogenesis of psoriasis.Entities:
Mesh：
Substances：
Year: 2001 PMID： 11705352 DOI： 10.1016/s0733-8635(05)70306-5
Source DB: PubMed Journal: Dermatol Clin ISSN： 0733-8635 Impact factor: 3.478